SCYNEXIS Company Profile (NASDAQ:SCYX)

About SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS logoSCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SCYX
  • CUSIP: N/A
  • Web: www.scynexis.com
Capitalization:
  • Market Cap: $56.24 million
  • Outstanding Shares: 26,722,000
Average Prices:
  • 50 Day Moving Avg: $1.84
  • 200 Day Moving Avg: $2.08
  • 52 Week Range: $1.52 - $5.51
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.74
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $256,999.00
  • Price / Sales: 253.70
  • Book Value: $1.20 per share
  • Price / Book: 2.03
Profitability:
  • EBIDTA: ($25,040,000.00)
  • Net Margins: -9,648.47%
  • Return on Equity: -64.04%
  • Return on Assets: -37.19%
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 10.89%
  • Quick Ratio: 10.89%
Misc:
  • Average Volume: 256,166 shs.
  • Beta: 0.32
  • Short Ratio: 12.29
 

Frequently Asked Questions for SCYNEXIS (NASDAQ:SCYX)

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) announced its quarterly earnings results on Monday, August, 8th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.04. The company had revenue of $0.06 million for the quarter. SCYNEXIS had a negative net margin of 9,648.47% and a negative return on equity of 64.04%. View SCYNEXIS's Earnings History.

Where is SCYNEXIS's stock going? Where will SCYNEXIS's stock price be in 2017?

8 brokerages have issued 12-month price targets for SCYNEXIS's stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate SCYNEXIS's share price to reach $11.25 in the next twelve months. View Analyst Ratings for SCYNEXIS.

Who are some of SCYNEXIS's key competitors?

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the folowing people:

  • Pamela J. Kirby Ph.D., Chairman of the Board
  • Marco Taglietti M.D., President, Chief Executive Officer, Director
  • Eric S. Francois, Chief Financial Officer
  • David Angulo M.D., Chief Medical Officer
  • Laurent Arthaud, Director
  • Steven C. Gilman Ph.D., Director
  • Ann F. Hanham Ph.D., Director
  • David C. Hastings, Director
  • Patrick J. Langlois Ph.D., Director

Who owns SCYNEXIS stock?

SCYNEXIS's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (16.31%), FMR LLC (3.61%), Vanguard Group Inc. (3.37%), DAFNA Capital Management LLC (1.96%), National Asset Management Inc. (1.19%) and Private Advisor Group LLC (0.78%). Company insiders that own SCYNEXIS stock include Ann Hanham, David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti and Patrick Machado. View Institutional Ownership Trends for SCYNEXIS.

Who sold SCYNEXIS stock? Who is selling SCYNEXIS stock?

SCYNEXIS's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Virtu KCG Holdings LLC. View Insider Buying and Selling for SCYNEXIS.

Who bought SCYNEXIS stock? Who is buying SCYNEXIS stock?

SCYNEXIS's stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, National Asset Management Inc., DAFNA Capital Management LLC, Vanguard Group Inc. and GSA Capital Partners LLP. Company insiders that have bought SCYNEXIS stock in the last two years include Ann Hanham, David C Hastings, Eric Francois, Gonzalez David Angulo, Guy Macdonald, Marco Taglietti and Patrick Machado. View Insider Buying and Selling for SCYNEXIS.

How do I buy SCYNEXIS stock?

Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYNEXIS stock can currently be purchased for approximately $2.44.


MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for SCYNEXIS (NASDAQ:SCYX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.25 (361.07% upside)

Analysts' Ratings History for SCYNEXIS (NASDAQ:SCYX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017HC WainwrightSet Price TargetBuy$14.00HighView Rating Details
8/7/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
5/30/2017AegisReiterated RatingBuyMediumView Rating Details
5/9/2017Needham & Company LLCDowngradeBuy -> HoldHighView Rating Details
3/14/2017GuggenheimReiterated RatingBuy$15.00HighView Rating Details
3/3/2017Royal Bank Of CanadaReiterated RatingOutperform$15.00 -> $11.00N/AView Rating Details
10/7/2016WBB SecuritiesUpgradeBuy -> Strong-Buy$8.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for SCYNEXIS (NASDAQ:SCYX)
Earnings by Quarter for SCYNEXIS (NASDAQ:SCYX)
Earnings History by Quarter for SCYNEXIS (NASDAQ SCYX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($0.52)($0.56)$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.63)($0.52)$0.06 millionViewN/AView Earnings Details
11/13/2015Q315($0.62)($0.60)$0.06 millionViewN/AView Earnings Details
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details
3/30/2015($0.71)($0.45)$5.30 millionViewN/AView Earnings Details
11/13/2014($0.53)($0.45)$4.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SCYNEXIS (NASDAQ:SCYX)
Current Year EPS Consensus Estimate: $-1.21 EPS
Next Year EPS Consensus Estimate: $-1.4 EPS

Dividends

Dividend History for SCYNEXIS (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for SCYNEXIS (NASDAQ:SCYX)
Insider Ownership Percentage: 3.91%
Institutional Ownership Percentage: 36.75%
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)
Institutional Ownership by Quarter for SCYNEXIS (NASDAQ:SCYX)
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/23/2017Marco TagliettiCEOBuy5,000$1.85$9,250.00View SEC Filing  
8/15/2017Marco TagliettiCEOBuy10,000$1.61$16,100.00View SEC Filing  
8/11/2017Gonzalez David AnguloInsiderBuy10,000$1.55$15,500.00View SEC Filing  
6/21/2017David C HastingsDirectorBuy20,000$1.75$35,000.00View SEC Filing  
5/12/2017Gonzalez David AnguloInsiderBuy15,000$1.70$25,500.00View SEC Filing  
5/12/2017Marco TagliettiCEOBuy25,000$1.69$42,250.00View SEC Filing  
12/21/2016Marco TagliettiCEOBuy25,000$3.30$82,500.00View SEC Filing  
12/16/2016Gonzalez David AnguloInsiderBuy4,000$3.25$13,000.00View SEC Filing  
9/15/2016Patrick MachadoDirectorBuy40,000$2.94$117,600.00View SEC Filing  
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.00View SEC Filing  
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.00View SEC Filing  
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.00View SEC Filing  
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00View SEC Filing  
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.00View SEC Filing  
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04View SEC Filing  
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00View SEC Filing  
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00View SEC Filing  
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00View SEC Filing  
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07View SEC Filing  
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.00View SEC Filing  
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.36View SEC Filing  
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.00View SEC Filing  
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for SCYNEXIS (NASDAQ:SCYX)
Latest Headlines for SCYNEXIS (NASDAQ:SCYX)
Source:
DateHeadline
seekingalpha.com logoSCYNEXIS (SCYX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 9:51 AM
finance.yahoo.com logoWhat Does SCYNEXIS Inc’s (SCYX) Share Price Indicate?
finance.yahoo.com - September 14 at 9:51 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - September 12 at 9:32 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - September 7 at 8:20 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 6 at 6:46 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - September 6 at 7:20 AM
finance.yahoo.com logoETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM
finance.yahoo.com logoETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM
finance.yahoo.com logoSCYNEXIS to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 9:49 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 29 at 10:21 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 26 at 6:22 AM
finance.yahoo.com logoSCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:23 AM
seekingalpha.com logoScynexis Q2 - Steady As She Goes - Seeking Alpha
seekingalpha.com - August 23 at 11:22 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - August 22 at 10:36 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - August 19 at 9:12 AM
americanbankingnews.com logoInsider Buying: SCYNEXIS, Inc. (SCYX) CEO Buys 10,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:24 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Given a $14.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 16 at 8:02 AM
globenewswire.com logo“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 4:26 PM
finance.yahoo.com logo“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
finance.yahoo.com - August 15 at 4:26 PM
globenewswire.com logoSCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 6:49 AM
finance.yahoo.com logoSCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
finance.yahoo.com - August 15 at 6:49 AM
americanbankingnews.com logoSCYNEXIS, Inc. (NASDAQ:SCYX) Insider Gonzalez David Angulo Purchases 10,000 Shares
www.americanbankingnews.com - August 15 at 12:16 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 12 at 6:38 PM
globenewswire.com logoSCYNEXIS Reports Second Quarter 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 7:19 AM
finance.yahoo.com logoSCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - August 9 at 7:19 AM
americanbankingnews.com logoRoth Capital Analysts Give SCYNEXIS Inc (NASDAQ:SCYX) a $9.00 Price Target
www.americanbankingnews.com - August 7 at 6:20 PM
globenewswire.com logoSCYNEXIS to Present at the Canaccord Genuity Growth Conference - GlobeNewswire (press release)
globenewswire.com - August 7 at 3:29 PM
feeds.benzinga.com logoSCYNEXIS to Present at the Canaccord Genuity Growth Conference
feeds.benzinga.com - August 7 at 10:25 AM
globenewswire.com logoSCYNEXIS Announces Initiation of Dosing in Phase 2 Study ... - GlobeNewswire (press release)
globenewswire.com - August 4 at 8:01 AM
finance.yahoo.com logoSCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
finance.yahoo.com - August 4 at 8:01 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - August 2 at 8:32 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 18 at 6:56 PM
americanbankingnews.com logoSCYNEXIS Inc (NASDAQ:SCYX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - July 14 at 11:40 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 12:44 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Coverage Initiated at Roth Capital
www.americanbankingnews.com - July 10 at 9:02 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Expected to Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 27 at 4:08 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 23 at 5:08 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Director David C. Hastings Acquires 20,000 Shares
www.americanbankingnews.com - June 22 at 10:56 AM
streetinsider.com logoScynexis (SCYX) Publishes Data on In Vitro Activity of SCYNEXIS ... - StreetInsider.com
www.streetinsider.com - June 15 at 4:32 PM
finance.yahoo.com logoNew Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains
finance.yahoo.com - June 15 at 4:32 PM
finance.yahoo.com logoETFs with exposure to SCYNEXIS, Inc. : June 14, 2017
finance.yahoo.com - June 15 at 12:26 AM
nasdaq.com logoSCYNEXIS, Inc. to Participate in the 2017 BIO International Convention - Nasdaq
www.nasdaq.com - June 13 at 10:46 AM
finance.yahoo.com logoSCYNEXIS, Inc. to Participate in the 2017 BIO International Convention
finance.yahoo.com - June 13 at 10:46 AM
americanbankingnews.com logoZacks Investment Research Upgrades SCYNEXIS Inc (SCYX) to "Buy"
www.americanbankingnews.com - June 10 at 12:32 PM
americanbankingnews.com logoSCYNEXIS Inc (SCYX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - June 8 at 7:24 AM
finance.yahoo.com logoEight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078
finance.yahoo.com - June 5 at 3:34 PM
americanbankingnews.com logoSCYNEXIS Inc (SCYX) Stock Rating Reaffirmed by Aegis
www.americanbankingnews.com - June 3 at 7:44 AM
americanbankingnews.com logo Analysts Expect SCYNEXIS Inc (SCYX) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 1 at 2:46 PM
americanbankingnews.com logoSCYNEXIS Inc (SCYX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 4:56 PM
finance.yahoo.com logoEight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS’ Lead Agent to Combat Serious and Life-threatening Fungal Infections
finance.yahoo.com - May 24 at 9:34 AM

Social

Chart

SCYNEXIS (SCYX) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff